PL1893620T3 - Podstawione spiro-związki i ich zastosowanie do wytwarzania przeciwbólowych środków leczniczych - Google Patents
Podstawione spiro-związki i ich zastosowanie do wytwarzania przeciwbólowych środków leczniczychInfo
- Publication number
- PL1893620T3 PL1893620T3 PL06742950T PL06742950T PL1893620T3 PL 1893620 T3 PL1893620 T3 PL 1893620T3 PL 06742950 T PL06742950 T PL 06742950T PL 06742950 T PL06742950 T PL 06742950T PL 1893620 T3 PL1893620 T3 PL 1893620T3
- Authority
- PL
- Poland
- Prior art keywords
- aliphatic compound
- gen
- optionally substituted
- cycloaliphatic group
- diastereomer
- Prior art date
Links
- 150000003413 spiro compounds Chemical class 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 150000007824 aliphatic compounds Chemical class 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000001953 Hypotension Diseases 0.000 abstract 1
- 229940122936 Vanilloid receptor 1 agonist Drugs 0.000 abstract 1
- 230000001195 anabolic effect Effects 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000000954 anitussive effect Effects 0.000 abstract 1
- 230000001539 anorectic effect Effects 0.000 abstract 1
- 230000001088 anti-asthma Effects 0.000 abstract 1
- 230000001773 anti-convulsant effect Effects 0.000 abstract 1
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000002460 anti-migrenic effect Effects 0.000 abstract 1
- 230000000648 anti-parkinson Effects 0.000 abstract 1
- 230000001139 anti-pruritic effect Effects 0.000 abstract 1
- 239000000924 antiasthmatic agent Substances 0.000 abstract 1
- 239000001961 anticonvulsive agent Substances 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 229960003965 antiepileptics Drugs 0.000 abstract 1
- 239000000939 antiparkinson agent Substances 0.000 abstract 1
- 239000003908 antipruritic agent Substances 0.000 abstract 1
- 229940124584 antitussives Drugs 0.000 abstract 1
- 230000001966 cerebroprotective effect Effects 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000021822 hypotensive Diseases 0.000 abstract 1
- 230000001077 hypotensive effect Effects 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 230000002584 immunomodulator Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 230000001777 nootropic effect Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 229940125725 tranquilizer Drugs 0.000 abstract 1
- 239000003204 tranquilizing agent Substances 0.000 abstract 1
- 230000002936 tranquilizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005023784A DE102005023784A1 (de) | 2005-05-19 | 2005-05-19 | Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| EP06742950A EP1893620B1 (de) | 2005-05-19 | 2006-05-17 | Substituierte spiro-verbindungen und deren verwendung zur herstellung von arzneimitteln gegen schmerz |
| PCT/EP2006/004651 WO2006122769A2 (de) | 2005-05-19 | 2006-05-17 | Substituierte spiro-verbindungen und deren verwendung zur herstellung von arzneimitteln gegen schmerz |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1893620T3 true PL1893620T3 (pl) | 2012-02-29 |
Family
ID=36646208
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10012043T PL2292625T3 (pl) | 2005-05-19 | 2006-05-17 | Podstawione spiro-związki i ich zastosowanie do wytwarzania przeciwbólowych środków leczniczych |
| PL06742950T PL1893620T3 (pl) | 2005-05-19 | 2006-05-17 | Podstawione spiro-związki i ich zastosowanie do wytwarzania przeciwbólowych środków leczniczych |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10012043T PL2292625T3 (pl) | 2005-05-19 | 2006-05-17 | Podstawione spiro-związki i ich zastosowanie do wytwarzania przeciwbólowych środków leczniczych |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20080214807A1 (pl) |
| EP (2) | EP1893620B1 (pl) |
| JP (1) | JP5376941B2 (pl) |
| AT (1) | ATE524478T1 (pl) |
| CA (1) | CA2608385A1 (pl) |
| CY (1) | CY1112137T1 (pl) |
| DE (1) | DE102005023784A1 (pl) |
| DK (1) | DK1893620T3 (pl) |
| ES (2) | ES2447815T3 (pl) |
| PL (2) | PL2292625T3 (pl) |
| PT (1) | PT1893620E (pl) |
| SI (1) | SI1893620T1 (pl) |
| WO (1) | WO2006122769A2 (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005044813A1 (de) | 2005-05-19 | 2007-10-04 | Grünenthal GmbH | Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| EP2064187A2 (en) * | 2006-08-25 | 2009-06-03 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 |
| EP2265588B1 (en) | 2008-02-27 | 2013-06-26 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF 11ß -HYDROXYSTEROID DEHYDROGENASE TYPE 1 |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| US8765735B2 (en) * | 2009-05-18 | 2014-07-01 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
| CN102762572A (zh) | 2010-02-01 | 2012-10-31 | 诺瓦提斯公司 | 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物 |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| EP2531490B1 (en) | 2010-02-02 | 2014-10-15 | Novartis AG | Cyclohexyl amide derivatives as crf receptor antagonists |
| TWI635082B (zh) | 2016-01-13 | 2018-09-11 | 歌林達有限公司 | ３－（（雜－）芳基）－８－胺基－２－側氧－１,３－二氮雜－螺－［４.５］－癸烷衍生物 |
| MX378995B (es) | 2016-01-13 | 2025-03-11 | Gruenenthal Gmbh | Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano. |
| RS60855B1 (sr) | 2016-01-13 | 2020-10-30 | Gruenenthal Gmbh | Derivati 8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2421797A (en) * | 1996-03-15 | 1997-10-01 | Du Pont Pharmaceuticals Company | Spirocycle integrin inhibitors |
| WO1998043962A1 (en) * | 1997-03-28 | 1998-10-08 | Du Pont Pharmaceuticals Company | Heterocyclic integrin inhibitor prodrugs |
| WO1999058139A2 (en) * | 1998-05-08 | 1999-11-18 | The Regents Of The University Of California | Methods for detecting and inhibiting angiogenesis |
| DE10130020A1 (de) * | 2001-06-25 | 2003-12-04 | Gruenenthal Gmbh | Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate |
| AU2003241453A1 (en) * | 2002-05-17 | 2003-12-02 | Janssen Pharmaceutica N.V. | Aminotetralin-derived urea modulators of vanilloid vr1 receptor |
| JP2005531574A (ja) * | 2002-05-22 | 2005-10-20 | アムジエン・インコーポレーテツド | 痛みの治療にバニロイド受容体リガンドとして使用するためのアミノ−ピリジン、−ピリジンおよびピリダジン誘導体 |
| DE102004032567A1 (de) * | 2004-07-05 | 2006-03-02 | Grünenthal GmbH | Substituierte 1-Propiolyl-piperazine |
-
2005
- 2005-05-19 DE DE102005023784A patent/DE102005023784A1/de not_active Withdrawn
-
2006
- 2006-05-17 PL PL10012043T patent/PL2292625T3/pl unknown
- 2006-05-17 US US11/914,866 patent/US20080214807A1/en not_active Abandoned
- 2006-05-17 SI SI200631204T patent/SI1893620T1/sl unknown
- 2006-05-17 WO PCT/EP2006/004651 patent/WO2006122769A2/de not_active Ceased
- 2006-05-17 AT AT06742950T patent/ATE524478T1/de active
- 2006-05-17 PT PT06742950T patent/PT1893620E/pt unknown
- 2006-05-17 PL PL06742950T patent/PL1893620T3/pl unknown
- 2006-05-17 EP EP06742950A patent/EP1893620B1/de not_active Expired - Lifetime
- 2006-05-17 JP JP2008511619A patent/JP5376941B2/ja not_active Expired - Fee Related
- 2006-05-17 ES ES10012043.5T patent/ES2447815T3/es not_active Expired - Lifetime
- 2006-05-17 EP EP10012043.5A patent/EP2292625B1/de not_active Expired - Lifetime
- 2006-05-17 CA CA002608385A patent/CA2608385A1/en not_active Abandoned
- 2006-05-17 DK DK06742950.6T patent/DK1893620T3/da active
- 2006-05-17 ES ES06742950T patent/ES2370038T3/es not_active Expired - Lifetime
-
2011
- 2011-12-05 CY CY20111101204T patent/CY1112137T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE102005023784A1 (de) | 2006-11-30 |
| ATE524478T1 (de) | 2011-09-15 |
| CA2608385A1 (en) | 2006-11-23 |
| CY1112137T1 (el) | 2015-11-04 |
| EP1893620B1 (de) | 2011-09-14 |
| ES2370038T3 (es) | 2011-12-12 |
| JP2008540592A (ja) | 2008-11-20 |
| EP2292625A1 (de) | 2011-03-09 |
| PT1893620E (pt) | 2011-10-31 |
| EP2292625B1 (de) | 2013-12-25 |
| ES2447815T3 (es) | 2014-03-13 |
| WO2006122769A3 (de) | 2007-03-15 |
| WO2006122769A2 (de) | 2006-11-23 |
| SI1893620T1 (sl) | 2012-04-30 |
| US20080214807A1 (en) | 2008-09-04 |
| EP1893620A2 (de) | 2008-03-05 |
| DK1893620T3 (da) | 2012-01-16 |
| JP5376941B2 (ja) | 2013-12-25 |
| PL2292625T3 (pl) | 2014-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1112137T1 (el) | Υποκατεστημενες σπειρο-ενωσεις και η χρηση αυτων για παραγωγη φαρμακευτικων μεσων εναντι πονου | |
| AU2011215704B2 (en) | Secondary structure stabilized NMDA receptor modulators and uses thereof | |
| US5804595A (en) | Kappa opioid receptor agonists | |
| PL378288A1 (pl) | Nowe pochodne benzoimidazolu oraz imidazo-pirydyny oraz ich zastosowanie jako leków | |
| CA2523261A1 (en) | Fused pyrimidine derivatives with crf activity | |
| US9603889B2 (en) | IAP antagonists | |
| EP2331571A1 (en) | Nmda receptor modulators and uses thereof | |
| MX2007007220A (es) | Compuestos de pirazolona como agonistas de receptor de glutamato metabotropico para el tratamiento de trastornos neurologicos y psiquiatricos. | |
| EA200400762A1 (ru) | Новые соединения, их использование в медицине, способ их изготовления и содержащие их фармацевтические композиции | |
| MY138086A (en) | Novel urea derivative as vanilloid receptor-1 antagonist | |
| JP2015505296A (ja) | Ｎｍｄａ受容体調節剤およびその使用 | |
| SE9904508D0 (sv) | New compounds | |
| PT1910381E (pt) | Compostos substituídos de 1-oxa-3,8-diazaspiro[4.5]decan-2- ona e sua utilização para produção de fármacos | |
| Wrobleski et al. | Cyclobutane derivatives as potent NK1 selective antagonists | |
| SE0102055D0 (sv) | New Compounds | |
| AR048973A1 (es) | (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)amida del acido 4-hidroxi-4-metil-piperidin-1-carboxilico. proceso de preparacion y composiciones farmaceuticas | |
| CY1110613T1 (el) | Υποκατεστημενες θειαζολες και η χρησιμοποιηση τους για την παρασκευη φαρμακων | |
| MXPA05011521A (es) | Derivado de 4,4-difluoro-1,2,3,4-tetrahidro-5h-1-benzazepina o una sal del mismo. | |
| CA2490002A1 (en) | Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | |
| SG146692A1 (en) | Melanin concentrating hormone antagonists | |
| Liu et al. | A mild and efficient synthesis of monofluorinated α-lactam pseudopeptides via a novel dehydrofluorination of Ugi products | |
| Paliwal et al. | Discovery of a novel, potent and orally active series of γ-lactams as selective NK1 antagonists | |
| US20120309811A1 (en) | P-glycoprotein-specific non-competitive peptide and peptidomimetic modulators | |
| Röhr et al. | Synthesis and stereoselective κ-receptor binding of methylated analogues of GR-89.696 | |
| EA015500B9 (ru) | Новые антагонисты мсн рецепторов |